Immunome (IMNM) Equity Average (2023 - 2025)
Immunome's Equity Average history spans 3 years, with the latest figure at $449.1 million for Q4 2025.
- For Q4 2025, Equity Average rose 126.79% year-over-year to $449.1 million; the TTM value through Dec 2025 reached $449.1 million, up 126.79%, while the annual FY2025 figure was $407.8 million, 170.89% up from the prior year.
- Equity Average reached $449.1 million in Q4 2025 per IMNM's latest filing, up from $266.6 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $449.1 million in Q4 2025 to a low of $7.7 million in Q3 2023.
- Average Equity Average over 3 years is $203.2 million, with a median of $234.4 million recorded in 2024.
- Peak YoY movement for Equity Average: surged 2941.03% in 2024, then grew 6.86% in 2025.
- A 3-year view of Equity Average shows it stood at $63.0 million in 2023, then surged by 214.45% to $198.0 million in 2024, then soared by 126.79% to $449.1 million in 2025.
- Per Business Quant, the three most recent readings for IMNM's Equity Average are $449.1 million (Q4 2025), $266.6 million (Q3 2025), and $288.2 million (Q2 2025).